174 related articles for article (PubMed ID: 33665180)
1. Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States.
Priyadarshini M; Prabhu VS; Snedecor SJ; Corman S; Kuter BJ; Nwankwo C; Chirovsky D; Myers E
Front Public Health; 2020; 8():624092. PubMed ID: 33665180
[No Abstract] [Full Text] [Related]
2. Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003.
Ekwueme DU; Chesson HW; Zhang KB; Balamurugan A
Cancer; 2008 Nov; 113(10 Suppl):2936-45. PubMed ID: 18980277
[TBL] [Abstract][Full Text] [Related]
3. Years of potential life lost and productivity losses from male urogenital cancer deaths--United States, 2004.
Li C; Ekwueme DU; Rim SH; Tangka FK
Urology; 2010 Sep; 76(3):528-35. PubMed ID: 20573389
[TBL] [Abstract][Full Text] [Related]
4. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
5. Years of potential life lost and productivity costs due to premature cancer-related mortality in Iran.
Khorasani S; Rezaei S; Rashidian H; Daroudi R
Asian Pac J Cancer Prev; 2015; 16(5):1845-50. PubMed ID: 25773835
[TBL] [Abstract][Full Text] [Related]
6. Lost Annual Productivity Costs Due to Uterine Cancer Deaths in the United States in 2014.
Corman S; Nwankwo C
J Womens Health (Larchmt); 2019 Jul; 28(7):929-933. PubMed ID: 31066608
[No Abstract] [Full Text] [Related]
7. Years of potential life lost and productivity costs due to premature mortality from six priority diseases in Tanzania, 2006-2015.
Rumisha SF; George J; Bwana VM; Mboera LEG
PLoS One; 2020; 15(6):e0234300. PubMed ID: 32516340
[TBL] [Abstract][Full Text] [Related]
8. Lost productivity due to head and neck cancer mortality in Hungary, Poland, and Romania.
Bencina G; Chami N; Hughes R; Weston G; Golusiński PJ
J Cancer Policy; 2022 Dec; 34():100366. PubMed ID: 36244644
[TBL] [Abstract][Full Text] [Related]
9. Temporal Trends and Projection of Cancer Attributable to Human Papillomavirus Infection in China, 2007-2030.
Duan R; Xu K; Huang L; Yuan M; Wang H; Qiao Y; Zhao F
Cancer Epidemiol Biomarkers Prev; 2022 May; 31(5):1130-1136. PubMed ID: 35266990
[TBL] [Abstract][Full Text] [Related]
10. Overview of the benefits and potential issues of the nonavalent HPV vaccine.
Mariani L; Preti M; Cristoforoni P; Stigliano CM; Perino A
Int J Gynaecol Obstet; 2017 Mar; 136(3):258-265. PubMed ID: 28087890
[TBL] [Abstract][Full Text] [Related]
11. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
12. Incidence Trends and Burden of Human Papillomavirus-Associated Cancers Among Women in the United States, 2001-2017.
Deshmukh AA; Suk R; Shiels MS; Damgacioglu H; Lin YY; Stier EA; Nyitray AG; Chiao EY; Nemutlu GS; Chhatwal J; Schmeler K; Sigel K; Sonawane K
J Natl Cancer Inst; 2021 Jun; 113(6):792-796. PubMed ID: 32833021
[TBL] [Abstract][Full Text] [Related]
13. Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China.
Duan R; Qiao Y; Clifford G; Zhao F
Cancer Med; 2020 Jan; 9(1):374-384. PubMed ID: 31714036
[TBL] [Abstract][Full Text] [Related]
14. Deaths from secondhand smoke exposure in the United States: economic implications.
Max W; Sung HY; Shi Y
Am J Public Health; 2012 Nov; 102(11):2173-80. PubMed ID: 22994180
[TBL] [Abstract][Full Text] [Related]
15. Burden of Cancers Related to Smoking among the Indonesian Population: Premature Mortality Costs and Years of Potential Life Lost.
Kristina SA; Endarti D; Prabandari YS; Ahsan A; Thavorncharoensap M
Asian Pac J Cancer Prev; 2015; 16(16):6903-8. PubMed ID: 26514465
[TBL] [Abstract][Full Text] [Related]
16. Cancer attributable to human papillomavirus infection in China: Burden and trends.
Lu Y; Li P; Luo G; Liu D; Zou H
Cancer; 2020 Aug; 126(16):3719-3732. PubMed ID: 32484937
[TBL] [Abstract][Full Text] [Related]
17. Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine.
López N; Torné A; Franco A; San-Martin M; Viayna E; Barrull C; Perulero N
Infect Agent Cancer; 2018; 13():15. PubMed ID: 29743937
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.
Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A
Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325
[TBL] [Abstract][Full Text] [Related]
19. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
Saraiya M; Unger ER; Thompson TD; Lynch CF; Hernandez BY; Lyu CW; Steinau M; Watson M; Wilkinson EJ; Hopenhayn C; Copeland G; Cozen W; Peters ES; Huang Y; Saber MS; Altekruse S; Goodman MT;
J Natl Cancer Inst; 2015 Jun; 107(6):djv086. PubMed ID: 25925419
[TBL] [Abstract][Full Text] [Related]
20. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
Zhang Z; Zhang J; Xia N; Zhao Q
Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
